MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer

Abstract excerpt

PURPOSE: Prostate-specific antigen testing has led to overtreatment of prostate cancer (PCa). Only a small subset of PCa patients will have an aggressive disease that requires intensive therapy, and there is currently no biomarker to predict disease aggressiveness at the time of surgery. MicroRNAs (miRNAs) are reported to be involved in PCa pathogenesis. METHODS: This study involved 105 participants. For the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Circular RNAs in diseases
• Share to MicroRNA in disease regulation
• Share to Prostate Cancer Treatment and Research